
U.S. Bars Mahmoud Abbas From UN General Assembly, Accusing Palestinian Authority of ‘Glorifying Terrorism’
By JOTAM CONFINO
|The administration says the temporary benefit put in place under the Biden administration amounts to corporate welfare for insurance companies and is no longer needed to stabilize the market.

More than 23 million Medicare recipients could be facing higher drug prices next year when the Trump administration allows the sunset of an optional expansion plan that cut prices on prescriptions.

By JOTAM CONFINO
|
By MATTHEW RICE
|
By DEAN KARAYANIS
|
By LIN CHIA-LUNG
|
By STEPHEN MOORE
|
By JENNIFER DOHERTY
|
By A.R. HOFFMAN
|
By THE NEW YORK SUN
|More than 23 million Medicare recipients could be facing higher drug prices next year when the Trump administration allows the sunset of an optional expansion plan that cut prices on prescriptions.
Already have a subscription? Sign in to continue reading
Cancel anytime
By continuing you agree to our Privacy Policy and Terms of Service.
Cancel anytime